Fresh analysis reveals that patients who come off blockbuster weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise plans.
Findings released in a major medical journal points out that while overweight people can lose a large proportion of their total mass while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"People purchasing these drugs should be informed of the risk of fast weight regain when the medication is stopped," warns expert Dr. Susan Jebb.
That rate of recovery suggests a reversion to original mass within about one and a half years.
Comparing Approaches
The study, which examined 37 of trials involving over 9,000 of patients, compared the effects of the injectable medications with other pills.
Scientists point out that individuals who lose weight through diet and exercise generally see a slower weight regain—around 100 grams monthly—after stopping.
The Reason for the Quick Regain
Experts propose the mechanism of the injections explains the amplified weight return.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone levels far above than normal could lead to the system to produce less of its own natural hormone, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' results in hunger is unsuppressed, making excessive eating a significant risk."
A Lifelong Disease?
Health authorities suggest the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Many experts argue that, due to the likelihood of weight regain, the treatment might need to be long-term.
This perspective is supported by drug manufacturers, who state that the findings "highlight the persistent nature of excess weight," similar to managing diseases like diabetes.
Patient Experiences
Users who have discontinued the medication explain a powerful return of hunger.
"It felt as if a switch activating and you're instantly starving," described an individual.
This difficulty is compounded if patients have not established permanent dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data show that millions of people in the UK have tried weight-loss jabs in the past year, with demand remaining high.
- Use is greater among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, experts caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone cure and long-term success likely depends on ongoing behavioural support.
